1. Journal Papers

This table browses all dspace content
Issue DateTitleJournal Title
2024Changes in the tumor immune microenvironment during disease progression in clear cell ovarian cancerINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2024Prediction of final pathology depending on preoperative myometrial invasion and grade assessment in low-risk endometrial cancer patients: A Korean Gynecologic Oncology Group ancillary study PLOS ONE
2025Loss of E-cadherin Activates EGFR-MEK/ERK Signaling, Promoting Cervical Cancer Progression CANCER GENOMICS & PROTEOMICS
2025Handgrip strength and diabetes in postmenopausal women: insights from the Korean National Health and Nutrition Examination Survey 2014-2019MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
2024Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045INTERNATIONAL JOURNAL OF CANCER
2024Postoperative Outcomes of Ovarian Preserving Surgery in Premenopausal Women With Adnexal TorsionOBSTETRICAL & GYNECOLOGICAL SURVEY
2025PM exposure during pregnancy affects childhood asthma via placental epigenetic changes: Neuronal differentiation and proliferation and Notch signaling pathwaysENVIRONMENTAL POLLUTION
2024Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapyJOURNAL OF GYNECOLOGIC ONCOLOGY
2024From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next Steps CANCERS
2024Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical TrialOBSTETRICAL & GYNECOLOGICAL SURVEY
2024Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trialLANCET
2024Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8 + TILs based on BRCA1/2 mutation status in epithelial ovarian cancers JOURNAL FOR IMMUNOTHERAPY OF CANCER
2024Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical CancerNEW ENGLAND JOURNAL OF MEDICINE
2024Effects of subcutaneous drain on wound dehiscence and infection in gynecological midline laparotomy: Secondary analysis of a Korean Gynecologic Oncology Group study (KGOG 4001)EJSO
2024Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial JOURNAL OF CLINICAL ONCOLOGY
2024Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysisGYNECOLOGIC ONCOLOGY
2024Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease NUTRIENTS
2024Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trialLANCET
2024Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines JOURNAL OF GYNECOLOGIC ONCOLOGY
2024Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trialGYNECOLOGIC ONCOLOGY

Recent Submissions

Browse

Links